Beghou

Beghou A long-term, agile partner for life sciences commercialization. Our work is data-driven and quantitative.

Beghou Consulting is a management consulting firm focusing on sales and marketing issues in the pharmaceutical and biotech industries. Our consultants bring extensive industry experience, proven modeling methods, and data management skills. We seek to develop and apply state-of-the art analytic models to address critical issues. While we perform most of our work in our offices, our consultants have a high degree of client contact. We work closely with client management during all phases of our projects to ensure that our recommendations and solutions have broad organizational support. Our dynamic, entrepreneurial and collaborative environment provides a unique blend of intense dedication to our clients with a casual work atmosphere that results in long-term client relationships. We pride ourselves in exceeding expectations by treating our clients like we would want to be treated and providing flexibility in all our engagements.

AI can help accelerate the foundational data work for first-time launch commercialization teams and create a trusted, du...
10/09/2026

AI can help accelerate the foundational data work for first-time launch commercialization teams and create a trusted, durable system from the start. How?

AI-assisted processes can play a practical role in ensuring data consistency, governance, and scalability by:
• Structuring data
• Reviewing data quality
• Creating metadata
• Documenting business rules
• Supporting compliance checks

This is an area where emerging biopharma companies have a unique advantage because the commercialization data foundation is being established for the first time. They can create near-term value while preparing for future analytics, automation, and AI-enabled commercialization.

Read our white paper to see how to prioritize other high-impact AI use cases and make the most of your first build: https://hubs.ly/Q04zK7-j0

First-time launch teams start with a structural advantage when it comes to building their commercialization data foundat...
10/08/2026

First-time launch teams start with a structural advantage when it comes to building their commercialization data foundation.

With no legacy systems, siloed processes, or entrenched vendor relationships to unwind, they can build an AI-enabled data foundation from day one that helps teams:
• Learn faster
• Act sooner
• Make launch decisions with greater confidence

𝗧𝗵𝗲 𝗿𝗲𝗾𝘂𝗶𝗿𝗲𝗺𝗲𝗻𝘁𝘀 𝗳𝗼𝗿 𝗮 𝗰𝗼𝗺𝗺𝗲𝗿𝗰𝗶𝗮𝗹𝗶𝘇𝗮𝘁𝗶𝗼𝗻 𝘀𝘆𝘀𝘁𝗲𝗺 𝗮𝗿𝗲 𝗰𝗵𝗮𝗻𝗴𝗶𝗻𝗴
The future of commercialization relies on connecting behavioral, market, medical, and operational context earlier.

For emerging biopharma companies establishing data and analytics capabilities for the first time, often with limited resources and amid launch uncertainty, creating a connected foundation can be challenging.

At the same time, AI, automation, and self-service analytics are changing what commercialization data foundations need to support.

𝗙𝗶𝗿𝘀𝘁-𝘁𝗶𝗺𝗲 𝗹𝗮𝘂𝗻𝗰𝗵 𝘁𝗲𝗮𝗺𝘀 𝗰𝗮𝗻 𝗯𝘂𝗶𝗹𝗱 𝘀𝗺𝗮𝗿𝘁𝗲𝗿 𝗮𝗻𝗱 𝗿𝗲𝗮𝗰𝘁 𝗳𝗮𝘀𝘁𝗲𝗿 𝗳𝗿𝗼𝗺 𝘁𝗵𝗲 𝘀𝘁𝗮𝗿𝘁
But these challenges can be viewed as a unique opportunity. Established companies often have to rethink how they connect years of siloed systems and processes.

Emerging biopharma teams can design a connected, AI-enabled commercialization solution from the beginning, leveling the playing field and creating a competitive advantage.

“With an AI-enabled data foundation, first-time launch teams can punch above their weight, combining data and insights to answer questions that once required weeks, months, or an entire team.”
Jenny Herritz, Partner, Beghou

Read our white paper to learn how to build an AI-enabled commercialization solution, including how to sequence investments, when to own vs rent, and examples of high-impact AI use cases:
https://hubs.ly/Q04zCxWH0

For first-time launch teams, building AI maturity alongside the launch model allows each capability to be developed when...
10/05/2026

For first-time launch teams, building AI maturity alongside the launch model allows each capability to be developed when it creates the most value and is the most feasible for the team's readiness.

𝗣𝗿𝗮𝗰𝘁𝗶𝗰𝗮𝗹 𝗿𝗼𝗮𝗱𝗺𝗮𝗽
By following a predefined AI roadmap, teams can support a commercial organization that's still taking shape without overburdening the teams:

𝗘𝗮𝗿𝗹𝘆 𝘀𝘁𝗮𝗴𝗲: 𝗕𝘂𝗶𝗹𝗱 𝗔𝗜 𝗿𝗲𝗮𝗱𝗶𝗻𝗲𝘀𝘀
• Establish the fundamentals, including clean data and governance.
• Start by setting AI priorities, decision rights, ownership, policies, and review expectations.
• Align commercial, medical, market access, and operations to work toward the same objectives.

𝗧𝗼𝗽𝗹𝗶𝗻𝗲 𝗱𝗮𝘁𝗮: 𝗦𝘁𝗿𝗲𝗻𝗴𝘁𝗵𝗲𝗻 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻-𝗺𝗮𝗸𝗶𝗻𝗴
• As launch assumptions become clearer, AI can help pressure-test scenarios, refine launch inputs, and identify blind spots.
• This is where teams can begin using workflow-specific AI to build experience and trust.
• At the same time, training should be provided on use cases, limits, and interpretation.

𝗟𝗮𝘂𝗻𝗰𝗵 𝗯𝘂𝗶𝗹𝗱: 𝗢𝗽𝗲𝗿𝗮𝘁𝗶𝗼𝗻𝗮𝗹𝗶𝘇𝗲 𝗔𝗜
• Closer to launch, the focus shifts from exploration to practical workflow integration.
• AI can move into reporting, alerts, signal monitoring, and feedback loops.
• Clear accountability is needed for how AI-supported insights are reviewed and acted on.

𝗣𝗼𝘀𝘁-𝗹𝗮𝘂𝗻𝗰𝗵 𝗼𝗽𝘁𝗶𝗺𝗶𝘇𝗮𝘁𝗶𝗼𝗻: 𝗦𝗰𝗮𝗹𝗲 𝘄𝗼𝗿𝗸𝗳𝗹𝗼𝘄𝘀
• Scaling works best after data, governance, workflows, and adoption have had time to mature.
• Teams can then expand into more advanced capabilities such as identifying which accounts are likely to begin treating and spotting referral patterns so patients don’t get lost.

See examples of how this roadmap is being applied by emerging biopharma teams to sequence AI capabilities leading up to their first launch: https://hubs.ly/Q04z7yDl0

For first-time launch teams, a key question is how much responsibility AI should have in the work itself and where human...
09/30/2026

For first-time launch teams, a key question is how much responsibility AI should have in the work itself and where humans should retain more control and oversight.

A useful way to think about AI’s role is to consider 𝗵𝗼𝘄 𝗼𝗳𝘁𝗲𝗻 𝗮 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗵𝗮𝗽𝗽𝗲𝗻𝘀 𝗮𝗻𝗱 𝗵𝗼𝘄 𝗰𝗿𝗶𝘁𝗶𝗰𝗮𝗹 𝘁𝗵𝗮𝘁 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗶𝘀. That helps determine where AI can automate work, where people should stay closely involved, and where an AI build may not be worth the effort.

𝗔𝘂𝘁𝗼𝗺𝗮𝘁𝗲 𝘄𝗵𝗲𝗿𝗲 𝗿𝘂𝗹𝗲𝘀 𝗮𝗿𝗲 𝗰𝗹𝗲𝗮𝗿 (𝗵𝗶𝗴𝗵 𝗳𝗿𝗲𝗾𝘂𝗲𝗻𝗰𝘆 + 𝗹𝗼𝘄 𝗰𝗿𝗶𝘁𝗶𝗰𝗮𝗹𝗶𝘁𝘆).
When volume is high and risk is manageable, automation can reduce manual effort:

• Routine data quality checks
• Structured data validation
• Repeatable formatting

𝗔𝘂𝗴𝗺𝗲𝗻𝘁 𝘄𝗶𝘁𝗵 𝗔𝗜 𝗮𝗻𝗱 𝗸𝗲𝗲𝗽 𝗵𝘂𝗺𝗮𝗻𝘀 𝗶𝗻 𝘁𝗵𝗲 𝗹𝗼𝗼𝗽 (𝗵𝗶𝗴𝗵 𝗳𝗿𝗲𝗾𝘂𝗲𝗻𝗰𝘆 + 𝗵𝗶𝗴𝗵 𝗰𝗿𝗶𝘁𝗶𝗰𝗮𝗹𝗶𝘁𝘆).
AI can help surface information, recommendations, or exceptions, while people retain review, escalation, and accountability:

• Next-best-action recommendations
• Field insight alerts
• Medical material reference checks
• Meeting summaries and content drafting

𝗗𝗲𝗽𝗿𝗶𝗼𝗿𝗶𝘁𝗶𝘇𝗲 𝗼𝗿 𝗵𝗮𝗻𝗱𝗹𝗲 𝗺𝗮𝗻𝘂𝗮𝗹𝗹𝘆 (𝗹𝗼𝘄 𝗳𝗿𝗲𝗾𝘂𝗲𝗻𝗰𝘆 + 𝗹𝗼𝘄 𝗰𝗿𝗶𝘁𝗶𝗰𝗮𝗹𝗶𝘁𝘆).
Some activities may simply not justify the effort required to configure, govern, and maintain AI:

• Vendor requirement summaries
• Desk research and market scans
• Broad platforms without defined use cases

𝗞𝗲𝗲𝗽 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗷𝘂𝗱𝗴𝗺𝗲𝗻𝘁 𝗵𝘂𝗺𝗮𝗻-𝗹𝗲𝗱 (𝗹𝗼𝘄 𝗳𝗿𝗲𝗾𝘂𝗲𝗻𝗰𝘆 + 𝗵𝗶𝗴𝗵 𝗰𝗿𝗶𝘁𝗶𝗰𝗮𝗹𝗶𝘁𝘆).
For decisions that happen less often but carry greater consequences, AI can support synthesis, scenario planning, and decision quality while people own the final judgment:

• Scenario planning
• Interpreting market signals
• Weighing trade-offs

The goal is to give AI enough responsibility to create value without handing over decisions that still require context, judgment, and clear human accountability.

See how human + AI workflows can be designed as the first-time launch commercial organization takes shape: https://hubs.ly/Q04ypDdV0

🎓 This fall, our team has been on the road connecting with students at some incredible universities, sharing what it's l...
09/29/2026

🎓 This fall, our team has been on the road connecting with students at some incredible universities, sharing what it's like to grow a career in consulting, analytics, and technology.

Over the past few weeks, we've had great conversations with talented students at UC Berkeley, the University of Pennsylvania, UNC-Chapel Hill, Boston College, and Duke University.

At Beghou, we believe in investing early in young talent through hands-on exposure to real client work, mentorship and collaboration with experienced leaders, and the chance to grow alongside teams solving meaningful problems for pharmaceutical and biotech companies.

We're looking forward to continuing these conversations at:
📍 Northwestern University — 9/29
📍 Boston University — 10/1
📍 University of Maryland — 10/2
📍 UCLA — 10/6
📍 UC San Diego — 10/7
📍 UC Davis — 10/14

If you are exploring a career where business, data, technology, and life sciences come together, we'd love to meet you. Come say hello to the Beghou team on campus → https://hubs.ly/Q04yBt6s0

Congratulations to Beghou’s Melissa McDevitt and Rajika Gupta for being recognized in Consulting Magazine’s 2026 Women L...
09/28/2026

Congratulations to Beghou’s Melissa McDevitt and Rajika Gupta for being recognized in Consulting Magazine’s 2026 Women Leaders Awards.

The awards celebrate women making a meaningful difference across the consulting profession. Melissa and Rajika represent two distinct ways that leadership creates impact, both within Beghou and for our clients.

Melissa, Partner and Head of Commercial Excellence, was recognized as a Mentorship Champion. Over 18 years at Beghou, she has grown from consultant to firm leader while helping create many of the programs, communities, and opportunities that help others do the same. From co-building our Trusted Advisor development program to founding the Women at Beghou employee resource group and mentoring colleagues across the firm, Melissa has made developing the next generation of leaders fundamental to Beghou.

Rajika, Associate Partner, was recognized as a Strategic Impact Leader. She consistently delivers on the work in front of her while always looking ahead to what clients need to operate more effectively over the long term. By helping organizations modernize operating models, improve efficiency, and build greater self-sufficiency, she turns individual client engagements into lasting partnerships.

What Melissa and Rajika share is a commitment to making the people and organizations around them stronger. They listen, build trust, and transform ideas into meaningful action.

We’re proud to see them named among this year’s Women Leaders. Congratulations, Melissa and Rajika.

For 30+ years, the biopharma industry has argued that slow development is a result of external factors. But with the FDA...
09/25/2026

For 30+ years, the biopharma industry has argued that slow development is a result of external factors. But with the FDA signaling openness toward expedited launch pathways and AI usage compressing standard program durations, these external constraints are easing up.

This reveals internal weaknesses in how companies are structured and operated:

• 𝗦𝗰𝗮𝗹𝗲-𝘂𝗽 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻𝘀 𝗵𝗮𝘃𝗲 𝗵𝗶𝘀𝘁𝗼𝗿𝗶𝗰𝗮𝗹𝗹𝘆 𝗯𝗲𝗲𝗻 𝗺𝗮𝗱𝗲 𝗮𝗳𝘁𝗲𝗿 𝗣𝗵𝗮𝘀𝗲 𝟯 𝗿𝗲𝗮𝗱𝗼𝘂𝘁, when the high probability of approval justified the capital investment. With shorter launch windows, companies must now make large, partially irreversible capital commitments under uncertainty.
• 𝗦𝗲𝗾𝘂𝗲𝗻𝘁𝗶𝗮𝗹 𝗵𝗮𝗻𝗱𝗼𝗳𝗳𝘀 𝗺𝗮𝗱𝗲 𝘀𝗲𝗻𝘀𝗲 𝘄𝗵𝗲𝗻 𝘁𝗶𝗺𝗲 𝘄𝗮𝘀 𝗮𝗯𝘂𝗻𝗱𝗮𝗻𝘁. But now, they look like self-imposed delays. Commercial, medical, and market access functions must now be active in parallel with development.
• 𝗠𝗶𝗱-𝘀𝗶𝘇𝗲𝗱 𝗽𝗵𝗮𝗿𝗺𝗮 𝗰𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀 𝗮𝗿𝗲 𝘁𝗵𝗲 𝗺𝗼𝘀𝘁 𝗮𝗳𝗳𝗲𝗰𝘁𝗲𝗱. They’re too large to be truly agile but too small to field teams in parallel. They have less slack than large pharma and less tolerance for distractions than emerging pharma.

What needs to change? Swipe 👉 for three key shifts Beghou’s Rohit Gupta recommends in his article for Clinical Leader. Link to read: https://hubs.ly/Q04ycwGj0

For first-time launch teams, prioritizing where to apply AI can help focus efforts, build early wins, and establish trus...
09/24/2026

For first-time launch teams, prioritizing where to apply AI can help focus efforts, build early wins, and establish trust in the underlying data and tech foundation.

Some use cases can create value early because they solve a practical problem, fit an existing workflow, and don’t require major transformation. Others may have strong potential but need more mature data, governance, workflow design, or adoption before they can scale.

A practical way to evaluate AI opportunities is to look at 𝗯𝗼𝘁𝗵 𝗯𝘂𝘀𝗶𝗻𝗲𝘀𝘀 𝗶𝗺𝗽𝗮𝗰𝘁 and 𝗶𝗺𝗽𝗹𝗲𝗺𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻 𝗰𝗼𝗺𝗽𝗹𝗲𝘅𝗶𝘁𝘆:

𝗣𝗶𝗹𝗼𝘁 𝗳𝗶𝗿𝘀𝘁:
Use cases that create value and build trust without requiring major transformation, such as:

• Medical material reference checks
• KOL/HCP profile synthesis
• Data quality checks for launch-critical feeds
• Targeting and segmentation refinement

𝗦𝗲𝗾𝘂𝗲𝗻𝗰𝗲 𝗱𝗲𝗹𝗶𝗯𝗲𝗿𝗮𝘁𝗲𝗹𝘆:
High-value opportunities that may need stronger data, governance, workflows, or adoption before scaling, such as:

• Next-best action recommendations
• AI-enabled provider engagement tools
• Field insight alerts

𝗨𝘀𝗲 𝘀𝗲𝗹𝗲𝗰𝘁𝗶𝘃𝗲𝗹𝘆:
Helpful productivity or learning opportunities that may not be central to launch readiness, such as:

• Desk research and market scans
• Meeting summaries and content drafting
• Vendor requirement summaries

𝗔𝘃𝗼𝗶𝗱 𝗼𝗿 𝗱𝗲𝗳𝗲𝗿:
High-effort opportunities with limited near-term value or readiness, such as:

• Advanced modeling before core data is trusted
• Agentic workflows before guardrails are defined
• Broad platforms without defined use cases
• Automation of high-stakes decisions

For emerging biopharma teams, the best AI use cases are those that fit the work, support launch readiness, and help the organization build confidence for what comes next.

See how emerging biopharma teams can right-size their AI build leading up to first launch: https://hubs.ly/Q04ycKRv0

Last week, we celebrated the expansion of Beghou’s New York office! 🗽 As our NYC team continues to grow and we welcome n...
09/22/2026

Last week, we celebrated the expansion of Beghou’s New York office! 🗽

As our NYC team continues to grow and we welcome new talent, we expanded into a larger space in our building. To mark the occasion, we brought together the NYC team and leaders from across Beghou to celebrate the milestone, have some fun and enjoy the skyline views.

The expanded space gives us more room to collaborate, develop new ideas and work closely with clients as we take on the new and increasingly complex challenges they’re facing.

Incorporating medical affairs input into field strategy later in the planning process risks a repetitive or fragmented s...
09/21/2026

Incorporating medical affairs input into field strategy later in the planning process risks a repetitive or fragmented stakeholder experience.

To avoid this, organizations are starting to build models that allow medical affairs and commercial to collectively contribute earlier and more intentionally toward field strategy and engagement planning while still respecting the distinct responsibilities and compliance guardrails each function must maintain.

Swipe 👉 to see how teams are thinking about how they involve medical affairs in their field strategy earlier.

Address

909 Davis Street, Suite 650
Evanston, IL
60201

Telephone

+18478645480

Website

Alerts

Be the first to know and let us send you an email when Beghou posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Beghou:

Shortcuts

Share